Phase Ib study of anlotinib in combination with anti-PD-L1 antibody (TQB2450) in patients with advanced acral melanoma.
Yu DuJie DaiLili MaoXiaoting WeiXue BaiLing ChenJing LinZhihong ChiChuanliang CuiXinan ShengBin LianBixia TangXuan WangXieqiao YanSiming LiLi ZhouJun GuoYu ChenLu SiPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
TQB2450 combined with anlotinib showed favorable tolerance and promising anti-tumor activity with a prolonged PFS compared with anti-PD1 monotherapy in patients with advanced acral melanoma.
Keyphrases